MedTrace Logo

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

NCT05221892 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2023-05-17

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the efficacy and safety of a combination of aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine and cyanocobalamin as adjuvant therapy for vertigo comparatively to ginger under a double-blind randomized study design.

Conditions

  • Vertigo

Interventions

DRUG

Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin

Tablets to be taken 30 minutes before each of 4 trips.

DRUG

Ginger

Tablets to be taken 30 minutes before each of 4 trips.

Sponsors & Collaborators

  • Fundação Educacional Serra dos Órgãos

    lead OTHER

Principal Investigators

  • carlos p nunes, MD · Fundação Educacional Serra dos Órgãos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-22
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221892 on ClinicalTrials.gov